Bibliography
- Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20
- Garber K. Pfizer's JAK inhibitor sails through phase III in rheumatoid arthritis. Nat Biotechnol 2011;29:467-8
- Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Patents 2009;19(10):1361-76
- Moore WJ, Richard D, Thorarensen A. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola. Expert Opin Ther Patents 2010;20(12):1703-22
- Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010;15(13-14):517-30
- Singh R, Masuda ES, Payan DG. Discovery and development of spleen tyrosine kinase (Syk) Inhibitors. J Med Chem 2012; PMID: 22257213
- Moretto AF, Dehnhardt C, Kaila N, The 2010 patent landscape for spleen tyrosine kinase inhibitors. Recent Patents Inflamm Allergy Drug Discov 2012; PMID: 22257213
- Portola Pharmaceuticals Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases Press release 27 October 2011
- Yamamoto N, Takeshita K, Shichijo M, The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003;306(3):1174-81
- Gilead Connecticut, Inc. Imidazopyrazine Syk Inhibitors. WO2010068258; 2010
- Gilead Connecticut, Inc. Imidazopyrazine Syk Inhibitors. WO2010068257; 2010
- Gilead Sciences, Inc. Imidazopyridine Syk Inhibitors. WO2011112995; 2011
- Liddle J, Atkinson FL, Barker MD, Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg Med Chem Lett 2011;21(20):6188-94
- SmithKline Beecham Corp. Pyrimdine Compounds Useful as Kinase Inhibitors. WO2008024634; 2008
- Glaxo Group Ltd. Pyrrolopyrimidine Derivatives as Syk Inhibitors. WO2007042298; 2007
- Glaxo Group Ltd. Pyrrolopyrimidine Derivatives as Syk Inhibitors. WO2007042299; 2007
- Glaxo group Ltd. 7-(1h-Pyrazol-4-yl)-1,6-Naphthyridine Compounds as Syk Inhibitors. WO2011134971; 2011
- Cywin CL, Zhao BP, McNeil DW, Discovery and SAR of novel naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett 2003;13(8):1415-18
- Boehringer Ingelheim International GmbH 4-Dimethylamino-phenyl Substituted Naphthyridines, and Use Thereof as Medicaments. WO2010015518; 2010
- Boehringer Ingelheim International GmbH Substituted Naphthyridines and Use Thereof as Medicines. WO2010015520; 2010